Clinical trials: Neutralizing Antibody
Rabies
Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults
Study design: Single-blind (subject and observer-blinded), active-controlled, randomized [6:2:1:2:1; CL184 + purified vero cell rabies vaccine (PVRV) vs. human rabies immune globulin (HRIG) + PVRV vs. placebo + PVRV vs.
- Trial name
- NCT01228383
- Testing
- Rabies virus-specific monoclonal antibodies, human polyclonal rabies immune globulin (HRIG), Human diploid cell vaccine (HDCV)
- Where
- India
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
HIV-1-infection
Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission
This is a phase I, randomized, open-label trial to investigate the safety of VRC07-523LS, PGDM1400LS and N-803 in combination with Ad26.Mos4.HIV, MVA-Bavarian Nordic (BN)-HIV and A244d11gp120/ALFQ vaccination, and the impact on…
- Trial name
- RV582 (NCT05769569)
- Testing
- VRC07-523LS, PGDM1400LS, N-803
- Where
- 2 sites in Thailand
- Volunteers
- healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
COVID-19 Vaccine, Corona Virus Infection
Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic presents a great challenge to global health. The first case was identified in December 2019 in Wuhan, China and since has infected nearly 100 million…
- Conditions
- COVID-19 Vaccine, Corona Virus Infection, Vaccine Adverse Reaction, Vaccine Response
- Trial name
- NCT04910971
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- LifeBridge Health
COVID-19
Use of Multiple Doses of Convalescent Plasma in Mechanically Intubated Patients With COVID-19
This study will assess the feasibility and safety of administering multiple doses of convalescent plasma to Covid-19 positive patients admitted to the Intensive Care Unit (ICU) receiving mechanical ventilation.
- Trial name
- NCT05595538
- Testing
- Multiple doses of anti-SARS-CoV-2 Convalescent Plasma
- Where
- Panama
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hospital Regional Dr. Rafael Estévez
Healthy Participants
Washington University WU 409: Immune Responses to Rabies Vaccine.
This study will evaluate the immune response to rabies vaccination persons 18 years and older. We will evaluate thirty healthy participants across three cohorts: 1) standard rabies pre-exposure prophylaxis regimen (two doses of…
- Trial name
- NCT07399951
- Testing
- Imovax, RabAvert, HyperRAB
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Rabies Virus Infection
Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials
To evaluate the antibody neutralization activity and safety of rabies mAb CBB 1 combination vaccine used in healthy people
- Trial name
- NCT06548139
- Testing
- Natural full human monoclonal antibody CBB 1 injection 50.0µg/kg, Natural full human monoclonal antibody CBB 1 injection 100.0µg/kg, Rabies Human Immunoglobulin (HRIG)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
HIV Infections
Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men
This study will evaluate the safety and efficacy of the human monoclonal antibody (mAb) VRC-HIVMAB060-00-AB (VRC01) in preventing HIV-1 infection among men and transgender (TG) persons who have sex with men, in North America…
- Trial name
- NCT02716675
- Testing
- VRC01
- Where
- 26 sites in United States, Brazil and 2 more
- Volunteers
- 2,699 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS COV-2 IgG Levels on Health Workers
SARS Cov_2 Incidence of Healthy Health Workers
Since the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) first emerged in Wuhan, China, on 12 December 2019, it has spread rapidly across the world and developed into a pandemic.
- Trial name
- NCT04845880
- Testing
- Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2
- Where
- Turkey (Türkiye)
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Baskent University
HIV
A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
HVTN 206/HPTN 114 is a randomized, double blind, controlled, phase 2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and neutralization of VRC07-523LS, PGT121.414.LS, and PGDM1400LS broadly neutralizing…
- Trial name
- NCT06812494
- Testing
- VRC07-523LS 400mg, PGT121.414.LS 400mg, PGDM1400LS 400mg
- Where
- 17 sites in United States, Brazil and 1 more
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Papilloma Virus Infection
Developing Methods to Investigate Additional Opportunities of HPV Vaccination by Using First-void Urine Samples
The main objective of this study is to develop protocols using FV urine that investigate in vitro whether infectious virions can be neutralized by HPV vaccination.
- Trial name
- HPV-VACPLUS (NCT04391647)
- Testing
- First-void urine collection, Blood draw
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
SARS-CoV-2 Infection
SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation
This is the first-in-human phase 1/2a trial of the inhaled administration of the SARS-CoV-2-neutralizing monoclonal antibody DZIF-10c in healthy volunteers and SARS-CoV-2-infected individuals.
- Trial name
- NCT04631705
- Testing
- DZIF-10c
- Where
- 6 sites in Germany
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Cologne
Human Immunodeficiency Virus
3BNC117 and 10-1074 in HIV Uninfected Adults
This is a phase 1 clinical trial to evaluate the safety and pharmacokinetics of the highly neutralizing anti-human immunodeficiency virus-1 monoclonal antibodies 3BNC117 and 10-1074, when given in combination, in human…
- Trial name
- NCT02824536
- Testing
- 3BNC117, 10-1074
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Post Other Specified Vaccination Encephalitis
6-year Antibody Check After Third Vaccination Against Japanese Encephalitis
The purpose of this study is to determine whether there are persisting antibodies against Japanese Encephalitis 6 years after the last vaccination with IXIARO(R) and to adapt or confirm mathematical models accordingly.
- Trial name
- NCT02039440
- Testing
- Blood draw
- Where
- Austria
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
COVID 19
B Cell Responses in COVID-19
In this study, we will develop techniques to optimize the in vitro production of human monoclonal antibodies.
- Trial name
- NCT06891170
- Where
- Italy
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
HIV Infections
Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women
This study will evaluate the safety and efficacy of the human monoclonal antibody (mAb) VRC-HIVMAB060-00-AB (VRC01) in preventing HIV-1 infection in high-risk, HIV-uninfected women.
- Trial name
- NCT02568215
- Testing
- VRC01
- Where
- 21 sites in Botswana, Kenya and 5 more
- Volunteers
- 1,924 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Upper Respiratory Tract Infections
Challenge Infection of Healthy Adult Volunteers With RSV A2
Background: One of the main causes of respiratory infections in children and adults is RSV. This stands for respiratory syncytial virus. Healthy adults usually get a cold when they get an infection with RSV.
- Trial name
- NCT03388645
- Testing
- 10^6.3 PFU of RSV A2, 10^7 PFU of RSV A2
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Virus Diseases
A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children
The purpose of this study is to evaluate the long-term persistence of immune responses approximately 5 years or more after simulated rabies post-exposure prophylaxis provided in 2012 according to Essen (1-1-1-1-1) or Zagreb…
- Trial name
- NCT02991872
- Testing
- Blood draw
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19 Vaccine, Safety Issues
ChulaCov19 Vaccine in Healthy Adults
This study will be conducted in 2 phases. Phase 1 of this study will be a single-centre, open label, dose escalation first in human (FIH) study conducted in 2 groups of healthy participants.
- Trial name
- NCT04566276
- Testing
- ChulaCov19 vaccine
- Where
- 2 sites in Thailand
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Healthy Adult Volunteers
Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination
The investigators conduct a prospective analysis to compare homologous and heterologous adenovirus vector ChAdOx1-nCov-19 (Astra-Zeneca) or SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine inoculation.
- Trial name
- NCT05074368
- Testing
- ChAdOx1-nCov-19 (Astra-Zeneca), SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
- Where
- Taiwan
- Volunteers
- 499 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Vaccinia, Virus Diseases
Evaluating the Human Immune Response to the JYNNEOS Vaccine
This study is designed to evaluate the magnitude and duration of the human adaptive immune response to the JYNNEOS Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine in the blood, lung mucosa, skin and bone marrow.
- Trial name
- NCT06366672
- Testing
- JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection, Phlebotomy, Research bronchoscopy
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine